Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ASH PREVIEW: Roche, Celgene, Gilead cancer drugs will grab headlines

This article was originally published in Scrip

Executive Summary

Roche, Celgene and Gilead Sciences cancer drugs are the focus for a number of doctors and investors at a big US medical meeting this weekend as new data will signal the commercial potential of the therapies in a growing blood disease market.

You may also be interested in...



Baxter's Advate helps prevent bleeding in one-year study of hemophiliacs

Using Baxter’s Advate drug as a preventative therapy helped significantly reduce bleeding incidents in a yearlong study.

Mylan CEO Bresch is looking to do a sizable deal

Mylan CEO Heather Bresch said she is looking to do a sizable deal that helps the US generic and specialty drug maker better compete in a consolidating field of rivals.

Biogen's Scangos sees potential to dominate hemophilia market

Biogen Idec CEO George Scangos is frank about his ambitions to dominate the market for hemophilia therapies, an opportunity he compares to the big biotech’s lead treating multiple sclerosis.

Topics

Related Companies

UsernamePublicRestriction

Register

SC023679

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel